Clinical Trial Update: S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial comparing S-1 plus docetaxel versus capecitabine plus docetaxel as first-line therapy for advanced breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• S-1 (tegafur/gimeracil/oteracil)
• Xeloda (capecitabine)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Breast Cancer Recurrent | Phase 2 | Status: UNKNOWN